Skip to main content

Andrew Joseph Muir

Professor of Medicine
Medicine, Gastroenterology
Duke Box 3913, Durham, NC 27710
03137B Hosp South, Durham, NC 27710

Selected Grants


Endocrinology and Metabolism Training Program

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2024 - 2029

The Southeastern Liver Health Cohort Study

ResearchCo Investigator · Awarded by North Carolina State University · 2023 - 2027

Duke Training Grant in Digestive Diseases and Nutrition

Inst. Training Prgm or CMEPrincipal Investigator · Awarded by National Institutes of Health · 1988 - 2027

Endocrinology and Metabolism Training Program

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2024 - 2029

The Southeastern Liver Health Cohort Study

ResearchCo Investigator · Awarded by North Carolina State University · 2023 - 2027

Duke Training Grant in Digestive Diseases and Nutrition

Inst. Training Prgm or CMEPrincipal Investigator · Awarded by National Institutes of Health · 1988 - 2027

Prediction and Prevention of Hepatic Decompensation in Patients with Cirrhosis

Clinical TrialCollaborator · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2021 - 2026

Abbreviated MRI for HCC screening in cirrhotic patients

ResearchCo Investigator · Awarded by Icahn School of Medicine at Mount Sinai · 2020 - 2025

GS-US-428-4194

Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2019 - 2024

Quantifying Enteric Metabolism of Branched-chain Amino Acids in Relation to Other Dietary and Microbiota Nutrients

ResearchAdvisor · Awarded by National Institutes of Health · 2022 - 2023

The Southeastern Liver Health Cohort Study

ResearchCo Investigator · Awarded by North Carolina State University · 2021 - 2023

CymaBay CB8025-31735

Clinical TrialPrincipal Investigator · Awarded by CymaBay Therapeutics · 2019 - 2022

Novartis - AMBER - VAY736

Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2018 - 2021

Medical Student Research Training Supplement

Inst. Training Prgm or CMEPrincipal Investigator · Awarded by National Institutes of Health · 2020 - 2021

HBV Clinical Research Network Site Application_Subcontract to UNC

Clinical TrialPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2015 - 2021

The Impact of Race, Ethnicity, and Socioeconomic Status on Listing for Liver Transplant after Referral

ResearchMentor · Awarded by American Association for the Study of Liver Diseases · 2018 - 2020

Sulfasalazine in PSC

Clinical TrialPrincipal Investigator · Awarded by Brigham and Women's Hospital · 2018 - 2020

Heart/Lung Transplant Study

Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2016 - 2020

RCT of an Integrated Treatment of Persons with Co-Occurring HCV and Alcohol Abuse

ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2013 - 2019

The Impact of Increasing Age on Waiting List and Post-Transplantation Outcomes for NAFLD Patients

FellowshipCo-Mentor · Awarded by American Association for the Study of Liver Diseases · 2017 - 2018

Regulation of T cell exhaustion by microRNA-720

ResearchCo Investigator · Awarded by National Institutes of Health · 2015 - 2017

NGM 14-0104

Clinical TrialPrincipal Investigator · Awarded by NGM Biopharmaceuticals · 2014 - 2017

Merck/MSD MK-5172-065-00

Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2014 - 2017

A Phase 2 open-label study in patients with recurrent Genotype 1 Hepatitis

Clinical TrialPrincipal Investigator · Awarded by Janssen Research & Development, LLC · 2014 - 2017

GS-US-342-1137

Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2014 - 2017

Evidera PSC

Clinical TrialPrincipal Investigator · Awarded by Evidera · 2014 - 2016

BMS Muir, AI443-113

Clinical TrialPrincipal Investigator · Awarded by The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership · 2013 - 2015

BMS AI443-102-0016 A Phase 3 Evaluation

Clinical TrialPrincipal Investigator · Awarded by The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership · 2013 - 2015

HPN-100-022

Clinical TrialPrincipal Investigator · Awarded by Hyperion Biotechnology, Inc. · 2014 - 2015

Pilot Study to Assess Changes in Immuneregulation with Phase of Chronic HBV Infection and Antiviral Therapy

Clinical TrialPrincipal Investigator · Awarded by The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership · 2013 - 2015

Moving Towards More Individualized Therapies in HIV/HCV Co-infected Patients

ResearchCo-Mentor · Awarded by National Institutes of Health · 2011 - 2015

Patient self-management and gene guided therapy for CHC

ResearchCo Investigator · Awarded by National Institutes of Health · 2012 - 2015

A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir

Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2013 - 2014

Gilead GS-US-334-0107 LOI

Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2012 - 2012

Integrated Treatment of Persons with Co-Occurring HCV and Alcohol Use/Abuse

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2008 - 2011

Uncertainity and Watchful Waiting in Chronic Hepatitis C

ResearchCo Investigator · Awarded by National Institutes of Health · 2005 - 2009

Interferon-y for the treatment of chronic HCV infection

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2001 - 2004

External Relationships


  • Cymabay
  • Gilead Sciences, Inc.
  • Ultragenyx

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.